A novel vitamin K1 2,3-epoxide reductase (VKOR) inhibitor, 3-acetyl-5- methyltetronic acid, reduces experimental glomerulonephritis

Journal of Veterinary Medical Science

Volumn 74, Issue 7, 2012, Pages 863-869

  Uchida, Masashi ^a   Sakaguchi, Yuka ^a   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

3 acetyl 5 methyltetronic acid (AMT); Glomerulonephritis (GN); Mesangial cell; Thy 1

Indexed keywords

RATTUS;

EID: 84864794383     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.11-0530     Document Type: Article

References (45)

1. Bentley, E. W. 1972. A review of anticoagulant rodenticides in current use. Bull. World Health Organ. 47: 275-280. [Medline]
2. Bjornsson, T. D. 1979. Use of serum creatinine concentrations to determine renal function. Clin. Pharmacokinet. 4: 200-222. [CrossRef] [Medline]
3. Brewster, U. C. and Perazella, M. A. 2004. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116: 263-272. [CrossRef] [Medline]
4. Brodsky, S. V., Satoskar, A., Chen, J. and Nadasdy, G. 2009. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am. J. Kidney Dis. 54: 1121-1126. [CrossRef] [Medline]
5. Brodsky, S. V., Nadasdy, T., Rovin, B. H. and Satoskar, A. A. 2011. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 80: 181-189. [CrossRef] [Medline]
6. Darling, I. M. and Morris, M. E. 1991. Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion. Pharm. Res. 8: 1318-1322. [CrossRef] [Medline]
7. Edward, C. 2007. Atlas of chronic kidney disease & end-stage renal disease in the United States: United States renal data system 2006 annual data report. Am. J. Kidney Dis. 49: S17-S32.
8. Eng, P. C., Chua, W. C., Chew, V. S. P. and Wong, P. T. 2008. Chronic angiotensin-converting enzyme inhibition up-regulates mouse kidney growth arrest specific-6 protein and the AXL subfamily of receptor tyrosine kinases. J. Renin Angiotensin Aldosterone Syst. 9: 238-241. [CrossRef] [Medline]
9. Eppel, G. A., Takazoe, K., Nikolic-Paterson, D. J. and Lan, H. Y. 2000. Characteristics of albumin processing during renal passage in anti-Thy1 and anti-glomerular basement membrane glomerulonephritis. Am. J. Kidney Dis. 35: 418-426. [CrossRef] [Medline]
10. Fogo, A. and Ichikawa, I. 1989. Evidence for the central role of glomerular growth promoters in the development of sclerosis. Semin. Nephrol. 9: 329-342. [Medline]
11. Gohda, T., Ra, C., Hamada, C. and Tsuge, T. 2008. Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittelforschung 58: 18-23. [Medline]
12. Hodson, E. M., Knight, J. F., Willis, N. S. and Craig, J. C. 2001. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. CD001533. [Medline]
13. Ito, S., Kuriyama, H., Iino, N. and Iguchi, S. 2003. Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist. Clin. Exp. Nephrol. 7: 290-295. [CrossRef] [Medline]
14. Jefferson, J. A. and Johonson, R. J. 1999. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J. Nephrol. 12: 297-307. [Medline]
15. Li, T., Chang, C. Y., Jin, D. Y. and Lin, P. J. 2004. Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544. [CrossRef] [Medline]
16. Limdi, N. A., Beasley, T. M., Baird, M. F., Goldstein, J. A., McGwin, G., Arnett, D. K., Acton, R. T. and Allon, M. 2009. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 20: 912-921.
17. Makibayashi, K., Tatematsu, M., Hirata, M. and Fukushima, N. 2001. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am. J. Pathol. 158: 1733-1741. [CrossRef] [Medline]
18. Methven, S., MacGregor, M. S., Traynor, J. P. and O'Reilly, D. S. 2010. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol. Dial. Transplant. 25: 2991-2996. [CrossRef] [Medline]
19. Mii, A., Shimizu, A., Masuda, Y. and Ishizaki, M. 2009. Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression. Lab. Invest. 89: 164-177. [CrossRef] [Medline]
20. Mochizuki, S., Dahlöf, B., Shimizu, M. and Ikewaki, K. 2007. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, openlabel, blinded endpoint morbidity-mortality study. Lancet 369: 1431-1439. [CrossRef] [Medline]
21. Noël, L. H. and Gubler, M. C. 2003. Histological classification of chronic glomerular diseases. Rev. Prat. 53: 2005-2012. [Medline]
22. Nolin, L. and Courteau, M. 1999. Management of IgA nephropathy: evidence-based recommendations. Kidney Int. Suppl. 70: S56-S62. [CrossRef] [Medline]
23. Olney, R. C. 2009. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm. Res. 72: 30-35. [Cross-Ref] [Medline]
24. Pavkov, M. E., Knowler, W. C., Hanson, R. L. and Bennett, P. H. 2008. Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am. J. Kidney Dis. 51: 759-766. [CrossRef] [Medline]
25. Pugsley, M. K. 2005. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc. West. Pharmacol. Soc. 48: 35-38. [Medline]
26. Qian, Y., Feldman, E., Pennathur, S. and Kretzler, M. 2008. From Fibrosis to Sclerosis; Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57: 1439-1445. [CrossRef] [Medline]
27. Robertshaw, M., Lai, K. N. and Swaminathan, R. 1989. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br. J. Clin. Pharmacol. 28: 275-280. [Medline]
28. Ruggenenti, P., Perna, A., Zoccali, C. and Gherardi, G. 2000. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 35: 1155-1165. [CrossRef] [Medline]
29. Rule, A. D. 2007. Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 16: 242-249. [CrossRef] [Medline]
30. Sadakane, C., Kase, Y., Koseki, J. and Hasegawa, Y. 2011. Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin. Exp. Nephrol. 15: 14-24. [CrossRef] [Medline]
31. Schmieder, R. E. 2005. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am. J. Hypertens. 18: 720-730. [CrossRef] [Medline]
32. Shimizu, F., Kawachi, H. and Orikasa, M. 1999. Role of mesangial cell damage in progressive renal disease. Kidney Blood Press. Res. 22: 5-12. [CrossRef] [Medline]
33. Striker, L. J., Doi, T. and Elliot, S. 1989. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin. Nephrol. 9: 318-328. [Medline]
34. THE GISEN GROUP 1997. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863. [CrossRef] [Medline]
35. Tomita, M., Sogabe, H., Nakazato, S. and Nakatsuji, S. 2005. Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure. Nephrol. Dial. Transplant. 20: 2358-2367. [CrossRef] [Medline]
36. Villa, L., Boor, P., Konieczny, A. and Kunter, U. 2011. Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrol. Dial. Transplant. 26: 3131-3143. [CrossRef] [Medline]
37. Wagner, J., Dechow, C., Morath, C. and Lehrke, I. 2000. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J. Am. Soc. Nephrol. 11: 1479-1487. [Medline]
38. Wang, Y., Zhen, Y., Shi, Y. and Chen, J. 2005. Vitamin K epoxide reductase: a protein involved in angiogenesis. Mol. Cancer Res. 3: 317-323. [CrossRef] [Medline]
39. Woo, K. T. 1999. Current therapeutic strategies in glomerulonephritis. Ann. Acad. Med. Singapore 28: 272-278. [Medline]
40. Yamamoto, T., Mundy, C. A., Wilson, C. B. and Blantz, R. C. 1991. Effect of mesangial cell lysis and proliferation on glomerular hemodynamics in the rat. Kidney Int. 40: 705-713. [Cross-Ref] [Medline]
41. Yanagita, M., Arai, H., Ishii, K. and Nakano, T. 2001. Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am. J. Pathol. 158: 1423-1432. [CrossRef] [Medline]
42. Yanagita, M. 2004. Gas6, Warfarin, and kidney diseases. Clin. Exp. Nephrol. 8: 304-309. [CrossRef] [Medline]
43. Yanagita, M. 2004. The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr. Opin. Nephrol. Hypertens. 13: 465-470. [CrossRef] [Medline]
44. Zhou, Y. H., Tang, L. G., Guo, S. L. and Jin, Z. C. 2011. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS ONE 6: e18788. [CrossRef] [Medline]
45. Zoran, L. B. 1994. Principles of Genitourinary Radiology, Urinary Tract Infections. George Thieme Verlag, Los Angeles.